SCM
AVTX icon

Squadron Capital Management’s Avalo Therapeutics AVTX Stock Holding History

Squadron Capital Management’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-130,000
Closed -$2.36M – 38
2025
Q4 		$2.36M Buy
+130,000
New +$2.19M 1% 28

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Squadron Capital Management's AVTX Position: Q1 2026 in Review

Squadron Capital Management sold out of Avalo Therapeutics (AVTX) in Q1 2026, closing a stake of 130,000 shares — an estimated $2.36M sold.

Squadron Capital Management first reported a position in AVTX in Q4 2025 and held it in 1 quarter. The position peaked at $2.36M in Q4 2025. 97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

  • Squadron Capital Management reported no remaining Avalo Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Squadron Capital Management sold 130,000 Avalo Therapeutics shares in Q1 2026, an estimated $2.36M.
  • Squadron Capital Management first reported a position in Avalo Therapeutics in Q4 2025 and held it in 1 quarter.
  • Squadron Capital Management's Avalo Therapeutics position peaked at $2.36M in Q4 2025.
  • 97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on Squadron Capital Management's 13F filing for Q1 2026, filed 15 May 2026.